Committee for Medicinal Products for Human Use (CHMP) recommended to grant a marketing authorisation for the following medicinal products:
1. Vildagliptin/metformin hydrochloride (Zomarist) 50 mg+850 mg and 50 mg+1000 mg, film-coated tablet: (Novartis )
2. Zypadhera, 210 mg, 300 mg, 405 mg powder for suspension for injection intended for treatment of schizophrenia: (Eli Lilly )
3. Xiliarx 50 mg tablets intended for treatment of type 2 diabetes mellitus:(Novartis Europharm Ltd.)
4. Irbesartan 75 mg , 150 mg and 300 mg film-coated tablets :(Krka)
5. Brinzolamide and Timolol (Azarga) 10 mg/ml / 5 mg/ml Eye drops, suspension intended the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension: (Alcon)
6. Tetrahydrobiopterin (Kuvan), 100 mg, soluble tablets intended for the treatment of hyperphenylalaninemia (HPA):(Merck KGaA)
No comments:
Post a Comment